{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:41:02Z","timestamp":1780105262912,"version":"3.54.0"},"reference-count":36,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Defining hidradenitis suppurativa (HS) subtypes was previously limited by small sample sizes and poor interrater reliability; no study has investigated subtype treatment responses. The objective of this analysis was to characterize HS clusters in adult patients with moderate to severe HS and evaluate secukinumab treatment responses between clusters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clusters were identified via an unsupervised machine learning clustering analysis using baseline data from the randomized, placebo\u2010controlled SUNSHINE (NCT03713619) and SUNRISE (NCT03713632) phase 3 trials. To assess treatment responses, patients received secukinumab every 2 (SECQ2W) or 4\u2009weeks (SECQ4W) or placebo, for 16\u2009weeks, after which, placebo patients randomly switched to SECQ2W\/SECQ4W, and SECQ2W\/SECQ4W patients maintained their original treatment, until week 52. Baseline outcomes included patient characteristics, disease characteristics and severity, HS\u2010associated comorbidities and previous treatment exposures. Treatment response was assessed via the HS clinical response (HiSCR), abscess and inflammatory nodule (AN) count, flares and NRS30 (skin pain).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Based on baseline data, three clusters were identified from 1084 patients (Cluster 1: 54.1%, Cluster 2: 17.8%, Cluster 3: 28.1%). Cluster 1 was predominantly female (65.4%) and was characterized by milder HS. Cluster 2 had more patients from the Asia Pacific, Middle East and Africa region (58.5%) and was characterized by moderate HS. Cluster 3 had the highest rates of previous exposure to biologics (45.9%) and prior HS\u2010related surgeries (47.5%) and was characterized by severe HS. SECQ2W and SECQ4W demonstrated efficacy versus placebo in all clusters at week 16; SECQ2W and SECQ4W efficacy was maintained to week 52. SECQ2W treatment showed a trend for greater efficacy versus SECQ4W in Cluster 3 through week 52.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Three HS clusters were identified. Secukinumab demonstrated benefit over placebo in all clusters. However, patients with more severe disease may take longer to respond and more frequent secukinumab dosing may be required for these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>SUNSHINE (NCT03713619) and SUNRISE (NCT03713632).<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.20234","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T08:48:40Z","timestamp":1722847720000},"page":"1410-1420","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the <scp>SUNSHINE<\/scp> and <scp>SUNRISE<\/scp> trials"],"prefix":"10.1111","volume":"39","author":[{"given":"Anna","family":"Passera","sequence":"first","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Muscianisi","sequence":"additional","affiliation":[{"name":"Novartis Gene Therapies  Bannockburn Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Demanse","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginette A.","family":"Okoye","sequence":"additional","affiliation":[{"name":"Department of Dermatology Howard University College of Medicine  Washington, D.C. USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor B. E.","family":"Jemec","sequence":"additional","affiliation":[{"name":"University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Mayo","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hsiao","sequence":"additional","affiliation":[{"name":"University of Southern California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Washington  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel S.","family":"Byrd","sequence":"additional","affiliation":[{"name":"Department of Dermatology Howard University College of Medicine  Washington, D.C. USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Wei","sequence":"additional","affiliation":[{"name":"Novartis Pharma Shanghai  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Uhlmann","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6407-3140","authenticated-orcid":false,"given":"Marc","family":"Vandemeulebroecke","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoba","family":"Ravichandran","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-4385","authenticated-orcid":false,"given":"Martina L.","family":"Porter","sequence":"additional","affiliation":[{"name":"Department of Dermatology Beth Israel Deaconess Medical Center and Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.052"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000431175"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.16691"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.045"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15233"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2012.01552.x"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.068"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503605"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/frai.2022.842306"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2021.0519"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.10.014"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15276"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.472"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.08.032"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000511045"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16183"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12655"},{"issue":"5","key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jaad.2015.07.047","article-title":"New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes","volume":"73","author":"Zee HH","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.048"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17695"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00022-3"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v070.i01"},{"key":"e_1_2_13_25_1","unstructured":"JosseJ editor.Principal component methods \u2013 hierarchical clustering \u2013 partitional clustering: why would we need to choose for visualizing data?2010."},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12648"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15671"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.043"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2021.07.003"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000508787"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14038"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2013-131994"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.04.001"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.065"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.044"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.02.013"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T07:20:44Z","timestamp":1754292044000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.20234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/jdv.20234"],"URL":"https:\/\/doi.org\/10.1111\/jdv.20234","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"2024-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}